
## **Carlo Barone**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3532783/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	13.7	2,276
2	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. Oncologist, 2011, 16, 228-238.	3.7	94
3	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24, 185-192.	3.7	89
4	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer, 2017, 117, 1278-1285.	6.4	33
5	Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients. Journal of Personalized Medicine, 2021, 11, 816.	2.5	12
6	Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer Journal of Clinical Oncology, 2017, 35, TPS810-TPS810.	1.6	3
7	Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies. Cancers, 2022, 14, 1052.	3.7	2
8	Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. Future Oncology, 2021, 17, 1749-1759.	2.4	0